An interventional study of Smartphone Apps in Asthma, sponsored by Ministry of Science and Technology, Taiwan. Completed at 1 site in Taiwan. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-08-02.
Sponsored by Ministry of Science and Technology, Taiwan · Not applicable, Interventional, and Supportive care
Among 88 studies in Asthma with a site in Taiwan — 13 open to participants now, 18 under way, 4 of them phase 3. Asthma · Taiwan.
Among the 88 studies in Asthma with a site in Taiwan, this one is the 46th largest by enrollment of the 72 interventional ones that give a count, is one of 6 that started in 2017, is one of 14 with no phase, and was the 72nd registered.
4,843 studies on the registry are indexed under Asthma; 602 are open to participants now.
Browse Asthma studies →13 of the 88 studies in Asthma with a site in Taiwan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Taiwan, Argentina, France and 7 more countries
Ages 12–17
AstraZeneca · Sites in Taiwan, Argentina, Egypt and 4 more countries
Ages 18+
Pfizer · Sites in Taiwan, United States, Argentina and 12 more countries
Ages 18–75
AstraZeneca · Sites in Taiwan, United States, Argentina and 18 more countries
Ages 18–75
GlaxoSmithKline · Sites in Taiwan, United States, Belgium and 9 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 146 take children under 18; 104 take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 79 across 3,342 interventional studies indexed under Asthma.
Median enrollment 274 across the 72 interventional studies, 225 across the 16 observational. Of the 55 that completed or were terminated, 26 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 88 have an industry lead sponsor. The 10 most frequent:
Ministry of Science and Technology, Taiwan is the lead sponsor of 8 studies on the registry; none are open to participants now.
Ministry of Science and Technology, Taiwan has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
6 of the studies in Asthma with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT06932263AstraZenecaDose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | 2027-06-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 88 studies in Asthma with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate whether a smartphone app based on the Global Initiative for Asthma (GINA) guidelines can improve asthma control and quality of life, and decrease asthma-related costs in children. The main question it to answer whether this app can improve asthma control, increase the quality of life, and decrease asthma-related costs.
Participants in the intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits, while the control group received reminder calls. Researchers will compare with the control group to see if the intervention receives more asthma control improvement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intervention group needs to download the smartphone apps and follow research protocol
Device: Smartphone Apps
The intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits
Number of participants both in intervention and control were assessed for the asthma severity change using Global Strategy for Asthma Management and Prevention (GINA) Guideline
The physician diagnoses asthma change at Taipei Hospital
Time frame: 3 and 6 months evaluation
All participants were assessed for the Asthma Control Test (ACT) change using ACT questionnaire from quality metric incorporated
The physician evaluate ACT change at Taipei Hospital for both group
Time frame: 3 and 6 months evaluation
All participants were assessed for the change of Quality of life using MiniPAQLQ
Physician and researchers evaluate the quality of life using MiniPAQLQ questionnaire
Time frame: 3 and 6 months evaluation
All participants were assessed for the Asthma Control Test change using Paediatric Asthma Quality of Life Questionnaire (PAQLQ) questionnaire
The physician evaluate PASS score change at Taipei Hospital for both group
Time frame: 3 and 6 months evaluation
All participants were assessed for the Peak Expiratory Flow (PEF) change using spirometry
The physician evaluate PEF change at Taipei Hospital for both group
Time frame: 3 and 6 months
All participants were assessed for the change of asthma cost using direct and indirect costs from national website
Researchers access the data from National Health Insurance database
Time frame: 3 and 6 months
All participants were assessed for their age in the baseline using data of birthday information
Nurses and or researchers is responsible in filling the data from the patient admission in the Hospital
Time frame: Baseline
All participants were assessed for the total serum IgE (kU/I) change from blood assessment
The researcher and physician record and evaluate the data
Time frame: 3 and 6 months evaluation
All participants were assessed for the comorbidities with atopic dermatitis using the health data record from Hospital and National Health Insurance
The researcher and physician record and evaluate the data
Time frame: Baseline
All participants were assessed for the comorbidities with allergic rhinitis using the health data record from Hospital and National Health Insurance
The researcher and physician record and evaluate the data
Time frame: Baseline
All participants were assessed for the family history of atopic disease using the health data record from Hospital and National Health Insurance
The researcher and physician record and evaluate the data
Time frame: Baseline
All participants were assessed for the systemic steroid dosage (prednisolone, mg), using the health data record from Hospital and National Health Insurance
The researcher and physician record and evaluate the data
Time frame: Baseline
All participants were assessed for the ICS Dosage (Seretide,mcg), using the health data record from Hospital and National Health Insurance
The researcher and physician record and evaluate the data
Time frame: Baseline
All participants were assessed for the Anti-leukotriene (montelukast, tab), using the health data record from Hospital and National Health Insurance
The researcher and physician record and evaluate the data
Time frame: Baseline
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — We don not plan to share individual participant data (IPD)
Ran from Feb 2017 to primary completion in Jun 2021, 52 months.
Of 599 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's 52 months is above that.
Counting every sponsor, half of 649 studies reached it within 23 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ministry of Science and Technology, Taiwan